Equity Overview
Price & Market Data
Price: $10.00
Daily Change: -$0.45 / 4.50%
Daily Range: $10.00 - $10.00
Market Cap: $5,528,997,376
Daily Volume: 1,500
Performance Metrics
1 Week: -4.31%
1 Month: 1.94%
3 Months: -13.49%
6 Months: 96.08%
1 Year: 390.2%
YTD: -4.31%
Company Details
Employees: 3497
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.